Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.45 |
| ▸ | FDPS | P14324 | 3/20 | 0.44 |
| ▸ | LIPE | Q05469 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18318680 | 0.84 | EPHX2 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGFDPS | |
| SCHEMBL18318896 | 0.83 | GPR119 (0.54) | — | |
| SCHEMBL18318483 | 0.83 | ACACB (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGFDPS | |
| SCHEMBL18319014 | 0.82 | MAPK10 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CGFDPS | |
| SCHEMBL18318344 | 0.81 | PIK3CD (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGKMT2A | |
| SCHEMBL18318933 | 0.81 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGFDPS | |
| SCHEMBL18318074 | 0.81 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGFDPS | |
| SCHEMBL18319381 | 0.80 | GSK3B (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGSCD | |
| SCHEMBL18318602 | 0.80 | PIK3CD (0.47) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL18318528 | 0.80 | MAPK7 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2019-05-23 | — | — | US | disclosed |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2019-03-05 | — | — | US | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | PIK3CD 990/4885PIK3CA 752/4885PIK3CB 1058/4885 |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | PIK3CD 1008/4885PIK3CA 776/4885PIK3CB 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.